Welcome to the Thrombosis.TV network. The Thrombosis.TV network brings the latest news, study updates,
and answers to frequently asked questions to our viewers. Explore key interviews with the
researchers themselves and ask questions of the author through our “Ask the Experts” feature.

Please select a video from the list below.

Dabigatran and Bleeding Risks in Older Patients

Elaine Hylek, MD, Professor of Medicine at Boston University discusses the risks of major bleeding with dabigatran, particularly in patients with atrial fibrillation. These patients are typically older; approximately 10-12% over age 80 have atrial fibrillation. The most common clinical problem with this age group is balancing the increasing risk of stroke with the accompanying increased risk of bleeding. Trials such as the RELY trial have shown a dramatically decreased risk of intracranial hemorrhage (ICH) and other major bleeding with dabigatran in these patients. For the management of bleeding with dabigatran, supportive therapy is often sufficient due to the relatively short half-life of approximately 10 hours (with good renal function). If necessary in the case of life-threatening bleeding, prothrombin complex concentrates (PCC’s) are likely the agent of first choice, and the data on new reversal agents is also very promising.

Thrombosis.TV is a leading destination for venous and arterial thrombosis education, news and expert opinion.
We combine a television background with the
latest science and insights to provide the latest
education. Working with our editorial board and
leading physicians in embolic disease, you will
find the most up to date information and important
educational tools